The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBASuperluminal Medicines is a Boston biotechnology company that combines structural biology and machine learning to design small molecule drugs for G protein-coupled receptors.
Superluminal's Hyperloop platform pairs cryo-electron microscopy, which produces many experimental receptor structures, with computational models for docking, molecule design, and predicting absorption and toxicity. The company focuses on endocrine and cardiometabolic diseases. Its lead program is a selective, biased MC4R agonist for rare genetic forms of obesity, such as Bardet-Biedl syndrome, and hypothalamic obesity, with a Phase 1 trial planned to start by the end of 2026. Superluminal also works with Eli Lilly on GPCR targets for cardiometabolic disease and obesity. In September 2026 it closed a $60 million Series B led by BVF Partners.
Leadership as of 14 November 2026.
Co-founder and CEO
Founder
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: